Gilead Sciences — Third Quarter 2026 Earnings Summary

Gilead Sciences reported third-quarter 2026 product sales of $8.3 billion, a 13% increase year-over-year, driven by strong performance in HIV, Trodelvy, and Livdelzi. The company raised its full-year 2026 product sales guidance to a range of $31.0 billion to $31.3 billion, reflecting robust growth in its base business despite lower Veklury sales. Diluted earnings per share for the quarter were $1.94, while non-GAAP diluted EPS reached $2.55. Additionally, Gilead announced FDA approval for the new HIV regimen Bixlenvo and expanded its HIV prevention licensing agreements for lenacapavir.